Latest News

The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.

Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

A recap of the FDA submissions and regulatory decisions in urology from October 2026.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.

Topline results are expected in November 2026 ahead of a planned sBLA submission.

Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,

A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.

Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.